More and more companies are looking for the best way to capture a piece of the expanding Chinese market, and Catalent Pharma Solutions intends to be among them. It has nailed down two deals that will give it manufacturing capacity there.
Catalent Pharma Solutions is betting big on the Chinese market, launching two joint ventures for its Softgel Technologies and Clinical Supply Solutions businesses.
Catalent Pharma Solutions is again expanding its manufacturing operations in North Carolina, this time to build new capacity for inhalation drugs.
Catalent Pharma Solutions says the demand for products at its plant in Swindon, U.K., is "changing," and so it is reducing head count there by nearly four dozen employees.
Catalent Pharma Solutions and Parexel International have joined forces to streamline the supply chain for clinical trials, saying their combined expertise can cover clients from early-stage planning to post-trial disposal.
Catalent Pharma Solutions has teamed up with South Korea's CTC Bio to attract clients looking to market solid oral dose and controlled-release products in the U.S. and Europe.
The Toronto CMO has a manufacturing services agreement with Clarity Pharmaceuticals, providing cGMP chemistry manufacturing, scale up, aseptic fill and finish services and analytical support for the Australian radiopharmaceutical company.
The NC facility ties into Catalent's plan to boost its offerings in areas like advanced blow-fill-seal aseptic delivery, delivery technologies and clinical trial supplies, among others.
Global CMO Catalent Pharma Solutions will unload its U.S. commercial packaging operations and sell it to venture capital group Frazier Healthcare for an undisclosed fee, according to a Catalent release.
Getting clinical trials right, and right the first time, is crucial for biopharma companies, especially as the cost of getting a drug to market is skyrocketing. Matthew Herper estimates in "The...